BCG 疫苗接种策略防治结核病：更新与展望。
BCG vaccination strategies against tuberculosis: updates and perspectives.
机构信息
College of Veterinary Medicine, China Agricultural University, Beijing, China.
Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, National Animal Transmissible Spongiform Encephalopathy Laboratory, China Agricultural University, Beijing, China.
出版信息
Hum Vaccin Immunother. 2021 Dec 2;17(12):5284-5295. doi: 10.1080/21645515.2021.2007711.
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB). However, BCG has variable efficacy and cannot completely prevent TB infection and transmission. Therefore, the worldwide prevalence of TB calls for urgent development of a more effective TB vaccine. In the absence of other approved vaccines, it is also necessary to improve the efficacy of BCG itself. Intravenous (IV) BCG administration and BCG revaccination strategies have recently shown promising results for clinical usage. Therefore, it is necessary for us to revisit the BCG vaccination strategies and summarize the current research updates related to BCG vaccination. This literature review provides an updated overview and perspectives of the immunization strategies against TB using BCG, which may inspire the following research on TB vaccine development.
卡介苗（BCG）是唯一获准用于预防结核病（TB）的疫苗。然而，BCG 的效果存在差异，无法完全预防 TB 感染和传播。因此，全球范围内结核病的流行迫切需要开发更有效的结核病疫苗。在没有其他获得批准的疫苗的情况下，也有必要提高 BCG 本身的功效。最近，静脉内（IV）BCG 给药和 BCG 再接种策略在临床应用中显示出了有前景的结果。因此，我们有必要重新审视 BCG 接种策略，并总结与 BCG 接种相关的最新研究进展。本文综述提供了使用 BCG 预防结核病的免疫策略的最新概述和观点，这可能会激发后续结核病疫苗开发的研究。
Zotero 插件